As of Thursday close, Johnson & Johnson’s (NYSE:JNJ) stock was down -$2.05, moving down -1.25 percent to $161.68. The average number of shares traded per day over the past five days has been 14,824,800 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.41 fall in that time frame. In the last twenty days, the average volume was 51,838,035, while in the previous 50 days, it was 26,635,607.
Since last month, JNJ stock retreated -4.84%. Shares of the company fell to $161.28 on 08/31/23, the lowest level in the past month. A 52-week high of $181.04 was reached on 01/06/23 after having rallying from a 52-week low of $150.11. Since the beginning of this year, JNJ’s stock price has dropped by -8.47% or -$14.97, and marked a new high 3 times. However, the stock has declined by -10.69% since its 52-week high.
JNJ stock investors should be aware that Johnson & Johnson (JNJ) stock had its last reported insider trading activity 37 days ago on Jul 26. Hait William, the of the company, disposed of 14,698 shares for $172.00 on Jul 26. It resulted in a $2,528,056 divestment by the insider. Fasolo Peter sold 20,000 shares at an average price of $170.32 on Jul 25. The insider now owns 102,696 shares following the transaction. On Jun 12, EVP, Chief TO and Risk Officer Wengel Kathryn E sold 12,465 shares at $160.00 apiece. The transaction was valued at $1,994,400.
Valuation Metrics
Right now, Johnson & Johnson (JNJ) has a P/E ratio of about 32.76. The stock’s beta is 0.54. Besides these, the trailing price-to-sales (P/S) ratio of 3.95, the price-to-book (PB) ratio of 5.59, and the price-to-cash flow ratio of 26.58 may also be considered.
The latest dividend of $1.19 per share was paid out, remained unchanged from last year’s $1.19. On Tuesday April 18 2023, a $0.06 dividend increase was announced.
Financial Health
In the three months ended June 29, Johnson & Johnson’s quick ratio stood at 0.90, while its current ratio was 1.10, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.45, and the total debt-to-equity ratio was 0.61. On the profitability front, the trailing twelve-month gross margin is 67.20% percent. In the year ended June 29, EBITDA margin amounted to 33.42%, whereas operating margins totaled 16.40%. Based on annual data, JNJ earned $63.85 billion in gross profit and brought in $94.94 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 15.40%. Return on equity (ROE) for the past 12 months was 17.60%.
In Johnson & Johnson’s quarter-end financial report for June 29, it reported total debt of $33.9 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. JNJ’s revenue rose 5.91% to $24.75 billion during the quarter, while net income inched up to $25.53 billion. While analysts expected Johnson & Johnson to report $2.62 quarterly earnings, the actual figure was $2.8 per share, beating the consensus estimate by 6.90%. During the quarter, the company generated $9.41 billion in EBITDA. The liabilities of Johnson & Johnson were 115.28 billion at the end of its most recent quarter ended June 29, and its total debt was $45.6 billion. The value of shareholders’ equity is $2.6 billion.
Technical Picture
This quick technical analysis looks at Johnson & Johnson’s (JNJ) price momentum. With a historical volatility rate of 16.89%, the RSI 9-day stood at 26.31% on 31 August.
With respect to its five-day moving average, the current Johnson & Johnson price is down by -2.07% percent or -$3.41. At present, JNJ shares trade -5.25% below its 20-day simple moving average and -1.61% percent below its 100-day simple moving average. However, the stock is currently trading approximately -1.34% below its SMA50 and -4.47% below its SMA200.
Stochastic coefficient K was 7.32% and Stochastic coefficient D was 10.29%, while ATR was 3.03. Given the Stochastic reading of 2.80% for the 14-day period, the RSI (14) reading has been calculated as 34.48%. As of today, the MACD Oscillator reading stands at -1.57, while the 14-day reading stands at -4.51.
Analyst Ratings
Johnson & Johnson (JNJ) has been rated Overweight by analysts. According to 0 brokerage firms, JNJ is a sell, and 14 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 2 analysts rate Johnson & Johnson stock as buy, with 6 recommending it as overweight.
With a median target price of $180.00, the current consensus forecast for the stock is $167.00 – $215.00. Based on these forecasts, analysts predict Johnson & Johnson (JNJ) will achieve an average price target of $182.00.
